Second, breast tumors have well-documented clinical subtypes (HER2+; ER/PR+, and Triple Negative), a useful feature for validation since we would expect tumors and cell lineages within them to partition largely by subtype. This evidence concerns the gene ERBB2 and breast neoplasm.